Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (91-100 of 284) with videos related to

Pageof 29
Sort By:
Cancers|June 10, 2023
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASVincenzo Formica, Cristina Morelli, Veronica Conca, et al.
Cancer Research and Treatment|November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-AnalysisChiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Journal for Immunotherapy of Cancer|November 11, 2020
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Fotios Loupakis, et al.
Critical Reviews in Oncology/Hematology|July 13, 2010
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational statusLorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Clinical Colorectal Cancer|April 7, 2019
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentRoberto Moretto, Federica Morano, Elena Ongaro, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
Clinics and Research in Hepatology and Gastroenterology|December 18, 2025
Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO groupAnnalice Gandini, Victoria Probst, Matteo Landi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Pharmacogenomics|September 24, 2010
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapyFrancesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, et al.
Pageof 29

Showing results (91-100 of 284) with videos related to

Sort By:
Pageof 29
Cancers|June 10, 2023
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASVincenzo Formica, Cristina Morelli, Veronica Conca, et al.
Cancer Research and Treatment|November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-AnalysisChiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
Journal for Immunotherapy of Cancer|November 11, 2020
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Fotios Loupakis, et al.
Critical Reviews in Oncology/Hematology|July 13, 2010
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational statusLorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2025
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trialThomas Aparicio, Anthony Turpin, Aziz Zaanan, et al.
Clinical Colorectal Cancer|April 7, 2019
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentRoberto Moretto, Federica Morano, Elena Ongaro, et al.
The Pharmacogenomics Journal|April 28, 2022
KDR genetic predictor of toxicities induced by sorafenib and regorafenibJulia C F Quintanilha, Susan Geyer, Amy S Etheridge, et al.
Clinics and Research in Hepatology and Gastroenterology|December 18, 2025
Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO groupAnnalice Gandini, Victoria Probst, Matteo Landi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Pharmacogenomics|September 24, 2010
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapyFrancesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, et al.
Pageof 29